Abstract
VEGF Signaling Pathways in Glioblastoma: Is the Evidence Sufficient for Widespread Use? A European Perspective
First uncontrolled trials suggest significant activity of bevacizumab in recurrent glioblastoma. However, many questions still remain unresolved, in particular in view of the occurrence of pseudo-responses, the development of gliomatosis cerebri, the unclear impact on survival, and the high costs associated with this treatment. Further studies need to focus the early identification of responders, better combination regimen, and on the assessment of survival benefit. The widespread use of bevacizumab prior to registration may actually become an obstacle for the answering of some of these questions.
Related Journals
Current Dentistry
Current Traditional Medicine
Adolescent Psychiatry
New Emirates Medical Journal
Current Radiopharmaceuticals
Recent Patents on Anti-Cancer Drug Discovery
Current Medicinal Chemistry - Anti-Cancer Agents
Current Cancer Therapy Reviews
Clinical Cancer Drugs
Anti-Cancer Agents in Medicinal Chemistry
Related Books
Andrology: Current and Future Developments
Male Infertility: An Integrative Manual of Western and Chinese Medicine
Recent Advances in Anesthesiology
Recent Advances in Anesthesiology
Recent Advances in Anesthesiology
Recent Advances in Anesthesiology
Awake Thoracic Surgery
The Anatomical Foundations of Regional Anesthesia and Acute Pain Medicine Macroanatomy Microanatomy Sonoanatomy Functional anatomy
Frontiers in Anti-infective Agents
Frontiers in Anti-infective Agents